Simulating complex patient populations with hierarchical learning effects to support methods development for post-market surveillance

Sharon E. Davis*, Henry Ssemaganda, Jejo D. Koola, Jialin Mao, Dax Westerman, Theodore Speroff, Usha S. Govindarajulu, Craig R. Ramsay, Art Sedrakyan, Lucila Ohno-Machado, Frederic S. Resnic, Michael E. Matheny

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Validating new algorithms, such as methods to disentangle intrinsic treatment risk from risk associated with experiential learning of novel treatments, often requires knowing the ground truth for data characteristics under investigation. Since the ground truth is inaccessible in real world data, simulation studies using synthetic datasets that mimic complex clinical environments are essential. We describe and evaluate a generalizable framework for injecting hierarchical learning effects within a robust data generation process that incorporates the magnitude of intrinsic risk and accounts for known critical elements in clinical data relationships. Methods: We present a multi-step data generating process with customizable options and flexible modules to support a variety of simulation requirements. Synthetic patients with nonlinear and correlated features are assigned to provider and institution case series. The probability of treatment and outcome assignment are associated with patient features based on user definitions. Risk due to experiential learning by providers and/or institutions when novel treatments are introduced is injected at various speeds and magnitudes. To further reflect real-world complexity, users can request missing values and omitted variables. We illustrate an implementation of our method in a case study using MIMIC-III data for reference patient feature distributions. Results: Realized data characteristics in the simulated data reflected specified values. Apparent deviations in treatment effects and feature distributions, though not statistically significant, were most common in small datasets (n < 3000) and attributable to random noise and variability in estimating realized values in small samples. When learning effects were specified, synthetic datasets exhibited changes in the probability of an adverse outcomes as cases accrued for the treatment group impacted by learning and stable probabilities as cases accrued for the treatment group not affected by learning. Conclusions: Our framework extends clinical data simulation techniques beyond generation of patient features to incorporate hierarchical learning effects. This enables the complex simulation studies required to develop and rigorously test algorithms developed to disentangle treatment safety signals from the effects of experiential learning. By supporting such efforts, this work can help identify training opportunities, avoid unwarranted restriction of access to medical advances, and hasten treatment improvements.

Original languageEnglish
Article number89
JournalBMC Medical Research Methodology
Volume23
Issue number1
Early online date11 Apr 2023
DOIs
Publication statusE-pub ahead of print - 11 Apr 2023

Bibliographical note

Funding Information:
This work was funded by a grant from the National Heart, Lung, and Blood Institute (NHLBI; grant number 1R01HL149948). The funding agency was not involved in the design of the study, collection and analysis of data, interpretation of results, or writing of the manuscript.

Publisher Copyright:
© 2023, The Author(s).

Data Availability Statement

The data that support the findings of this study are available from the MIMIC project and made available through the MIT Laboratory for Computational Physiology. These data are publicly available at https://mimic.mit.edu/ from the original distributor through data use agreements.

Keywords

  • Hierarchical learning effects
  • Learning effects
  • Medical devices
  • Post-market safety surveillance
  • Simulations
  • Synthetic clinical data

Fingerprint

Dive into the research topics of 'Simulating complex patient populations with hierarchical learning effects to support methods development for post-market surveillance'. Together they form a unique fingerprint.

Cite this